1 / 14

Dyspepsia

Dyspepsia. Resident Teaching Rounds Steve Radke August 11, 2003 References: Ontario Program for Optimal Therapeutics, Ontario Guidelines for PUD and GERD Guidelines 2000

coty
Télécharger la présentation

Dyspepsia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dyspepsia Resident Teaching Rounds Steve Radke August 11, 2003 References: Ontario Program for Optimal Therapeutics, Ontario Guidelines for PUD and GERD Guidelines 2000 Sander et al, “Evidence based approach to the management of uninvestigated dyspepsia in the era of H. pylori. CMAJ, June 13, 2000;162 (12 Suppl)

  2. Dyspepsia • Introduction • PUD/GERD - overview • Investigations • Approach to dyspepsia • NSAID induced PUD • Recurrent PUD • Take home messages

  3. Dyspepsia • - pain or discomfort in upper abdomen • heartburn • acid regurgitation • excessive burping/belching • abdominal bloating, nausea • overall prevalence 29% • DU or GU - 15-25% • Reflux esophagitis - 5-15% • Esophageal or gastric CA - < 2%

  4. PUD • Lifetime incidence: men 10%, women 4% • classic sxs: • localized epigastric pain • usually intermittent • often relieved with food • poor correlation b/n sxs and ulcers

  5. PUD • Etiology: • H. pylori • associated with 90-95% DU, 60-80% GU • NSAIDs • including ASA • smoking, ETOH • benign or malignant tumors

  6. GERD • Retrosternal burning and regurgitation • 89-95% specificity for GERD • worse after meals • exacerbated by position • transiently relieved by antacids • atypical presentations: • hoarseness, cough, asthma, dysphagia • poor correlation b/n sxs and grade of esophagitis • most patients have no findings on endoscopy

  7. GERD • Complications: • esophagitis • stricture • Barrett’s esophagus • esophageal adenocarcinoma • occurs in 2.5-24% of pts • Drug-Induced GERD • anticholinergics (e.g.. TCA), CCB, nitrates, benzos, opioids, OCP, bisphosphinates

  8. Investigations • endoscopic tests • histology, culture, rapid urease test • non-endoscopic • urea breath test, serology

  9. H. Pylori Serology • NPV - 90% • PPV - decr. as prevalence decr. • results in increased risk of false positive • < 50 yo, PPV 52-72% • Remains positive >6-12 months post Rx • not recommended to confirm eradication

  10. Urea Breath Test • PPV - 90% • NPV - 90% - irrespective of incidence • C13, C14 • preferred test • C13 - not covered by OHIP • C14 - only available in few major centres • can be used to confirm eradication • NB: pt must be > 4 wks post Rx, and > 1 week off of PPI or H2RA

  11. Approach to Dyspepsia • See handout • Red Flags: “ABCDV” • A - age >50, anemia, abdo mass • B - bleeding (GIB) • C - constitutional sxs • D - dysphagia • V - vomiting

  12. NSAID induced PUD • Prevention: • PPI • cytoprotective agent - mesoprostol 200ug tid • High dose H2RA - ranitidine 300mg bid • COX-2? • 2 or more of: • Previous GIB • Previous peptic ulcer • Age >75 yo • Hx of cardiovascular dz

  13. PUD recurrence • If H. pylori +ve • recurrence rate <5% / yr • confirm with UBT or endo. (not serology) • treat with alternate regime that does NOT have the same 2 ABx as initial Rx - x 14d • If H. pylori -ve • review NSAID use, smoking, etoh • refer for endoscopy

  14. Take home messages: • Red flags - “ABCDV” • Retrosternal burning and regurgitation • 89-95% specificity for GERD • H. pylori serology - limitations • Consider prevention in high risk pts taking NSAIDS (including ASA) • Always consider scope

More Related